In a 13D filing
yesterday morning on Bradley Pharmaceuticals Inc. (BDY
), President and CEO Daniel Glassman submitted a proposal to acquire all of the outstanding equity at a cash purchase price of $21.50 per share.
Bradley Pharmaceuticals confirmed the receipt of the bid and said they have formed a special committee to review the offer as well as other strategic alternatives.
Shares of BDY closed at $18.44 on Friday but jumped to $22.35 following the announcement yesterday.
BDY 1-yr chart
How did this change your view of ?
This impact ()
Thanks for sharing your thoughts.
Submit & View ResultsSkip to results »